Company Focus
Bristol Myers Squibb
Latest Bristol Myers Squibb News
Biotechnology
Japanese pharma major Takeda today announced positive top-line results for the Phase III, randomized, multicenter, double-blind study comparing zasocitinib (TAK-279), an investigational, next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, to deucravacitinib in adults with moderate-to-severe plaque psoriasis (PsO). 11 June 2026
Related News
Insights
Company Spotlight
A privately-held life sciences company with an integrated drug discovery and chemical biology platform.
Latest News & Features of interest to Bristol Myers Squibb
Biotechnology
M&A featured heavily last week, with Incyte announcing plans to buy Vega Therapeutics, a subsidiary of Star Therapeutics, for up to $2 billion. Then came UK pharma major GSK’s revelation of an agreement to acquire US firm Nuvalent for up to $10.6 billion. Also of note, US biotech Cartesian Therapeutics entered into a licensing deal with China’s WestGene Biopharma on CAR-T therapies for autoimmune diseases. Sweden’s Camurus was served another complete response letter (CRL) by the US Food and Drug Administration (FDA) on its filing for Oclaiz (CAM2029). 14 June 2026
Pharmaceutical
The US Food and Drug Administration (FDA) has approved AstraZeneca’s Truqap (capivasertib) in combination with abiraterone and prednisone as the first and only targeted treatment for adult patients with PTEN-deficient metastatic androgen pathway modulation-naïve or sensitive (mAPMN/S) prostate cancer. 13 June 2026
Biotechnology
Rocket Pharmaceuticals announced the closing of the sale of its Rare Pediatric Disease Priority Review Voucher (PRV) for gross proceeds of $180 million. The firm’s shares rose 5.6% to $2.81 following the announcement. 12 June 2026
Biotechnology
UK cell therapy company Autolus Therapeutics has won the 2026 Prix Galien UK Award for Best Biotechnology Product for Aucatzyl (obecabtagene autoleucel), its CAR-T therapy for adult acute lymphoblastic leukemia. 12 June 2026
Pharmaceutical
AbbVie today announced new Phase III data on a fixed-duration venetoclax-based combination at the European Hematology Association (EHA) 2026 Congress taking place June 11-14 in Stockholm, Sweden. 12 June 2026
Biotechnology
US biopharma Adial Pharmaceuticals has acquired Azora Therapeutics and lined up a private placement worth up to $64 million, broadening its pipeline beyond its historical focus on addiction disorders. 12 June 2026
Biotechnology
US cardiovascular biotech Kardigan is seeking to raise up to $373.3 million in a Nasdaq initial public offering, as it looks to fund a pipeline of clinical-stage heart disease programs. 12 June 2026
Biotechnology
A major UK Biobank epigenetics project will add another layer of data to one of the world’s most important biomedical research resources. The £16 million ($22 million) study will be led by the University of Exeter. 12 June 2026
Biotechnology
Japanese pharma major Takeda today announced positive top-line results for the Phase III, randomized, multicenter, double-blind study comparing zasocitinib (TAK-279), an investigational, next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, to deucravacitinib in adults with moderate-to-severe plaque psoriasis (PsO). 11 June 2026
Pharmaceutical
Spanish plasma-derived medicines company Grifols has held the ground-breaking ceremony for its new plant in Lliçà de Vall (Barcelona). 11 June 2026
Latest In Brief for Bristol Myers Squibb
Biotechnology
US biotech Incyte Pharma is nearing a deal for up to $2 billion to buy privately held blood disorder drug developer Star Therapeutics amid a wave of acquisitions by midsized drugmakers looking to supplement their pipelines, according to a Financial Times report. 8 June 2026
Copyright © The Pharma Letter 2026
| Headless Content Management with Blaze